Objective: To determine the incidence of prostate cancer identified on holmium enucleation of the prostate (HoLEP) specimens and evaluate variables associated with prostate cancer identification.
Introduction
Benign prostatic hyperplasia (BPH) affects a significant proportion of men in the United States with 70% of men in their seventh decade demonstrating histologic evidence and 40% displaying moderate to severe urinary symptoms 1 . Many will undergo active intervention with 912 per 100,000 men in the US undergoing a BPH procedure in 2008 2 . While TURP remains the most common active intervention for BPH 2, 3 , a wellestablished alternative is holmium laser enucleation of the prostate (HoLEP). HoLEP, initially described in 1996, reliably provides a more complete resection when compared with TURP, especially for large glands, with a superior safety profile 4, 5 . As with TURP, HoLEP is a procedure that provides tissue for pathologic analysis.
Before the adoption of prostate specific antigen (PSA) screening, almost 20% of prostate cancer was diagnosed from TURP [6] [7] [8] . However, since the introduction of PSA screening, this rate has declined significantly to 6-8% 8 . Previous studies have demonstrated that up to 12% of men undergoing HoLEP will be found to have prostate cancer in their analyzed tissue 9, 10 . Most studies have suggested that prostate cancer identified on HoLEP is generally indolent but some men may ultimately require subsequent treatment of their prostate cancer. In our experience, post-HoLEP robotassisted radical prostatectomy, although feasible with encouraging oncologic outcomes, is a more challenging operation associated with longer functional recovery times compared to historical controls 11 . Thus, identifying men at increased risk for clinically significant prostate cancer is an important consideration in managing patients with BPH disease who are considering enucleation surgery.
Our primary objective was to identify the incidence of prostate cancer identified by HoLEP in men with no history of prostate cancer. Additionally, we sought to determine preoperative variables that can be used to predict the presence of prostate 4 cancer in men undergoing HoLEP and to examine the burden of prostate cancer disease in this at risk patient population.
Methods

A retrospective analysis of patients who underwent HoLEP at IU Health
Methodist Hospital between 1998 and 2013 was performed. Patients with a prior history of prostate cancer diagnosis were eliminated from the analysis (n=34). Pre-operative data including age, PSA, transrectal ultrasonography (TRUS) of prostatic volume, and PSA density were collected. Additionally, post-operative data including final specimen weight and pathological tissue findings were recorded. Patients without pre-operative PSA were eliminated (n=221). Patients with elevated PSAs (at the referring urologist's discretion) had negative pre-operative prostate biopsies. Prostate volume as assessed by TRUS was identified for 76% of patients. PSA density was calculated from preoperative PSA and TRUS prostate volume and was available for 75% of patients.
We acknowledge that the likelihood of identifying prostate cancer may vary between patients with a history of TRUS biopsy and those without; however, to the extent of our documentation, the detection of cancer at the time of HoLEP did not vary between patient populations (p=0.314).
HoLEP was performed in similar fashion to our previously described technique 12 .
Briefly, using a 550 micron end firing laser fiber through a 28 Fr continuous flow resectoscope, the transition zone of the prostate was completely enucleated. Next, using a Lumenis morcellator (Yokneam, Israel), morcellation was completed removing the excised tissue from the bladder and prostatic fossa. The entire HoLEP specimen was submitted for pathologic analysis by dedicated genitourinary pathologists.
The relationship between pre-and post-operative variables and identification of the presence of prostate cancer was assessed using univariate and multivariate logistic 
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Prediction of prostate cancer
On univariate logistic regression analysis, age and pre-operative PSA were significantly associated with increased odds of identifying prostate cancer on final pathological analysis after HoLEP ( Table 2 ). The weight of the HoLEP specimen was associated with decreased odds of prostate cancer identification in the HoLEP specimen ( Table 2 ). On multivariate logistic regression, age, pre-operative PSA and decreasing specimen weight remained significantly associated with the presence of prostate cancer (Table 2 ). Figure 1 depicts the relationship between age and identification of prostate cancer when adjusting for pre-operative PSA and HoLEP specimen weight. Patients who were 80 years of age were at 20% predicted probability of having prostate cancer identified on HoLEP (<0.001).
Prediction of Gleason 7 or higher prostate cancer
Of the 103 patients with prostate cancer, 80 were Gleason 6 or less (78%), 14
were Gleason 7 (12 Gleason 3+4; 2 Gleason 4+3), and 9 were Gleason 8 or higher.
Univariate regression results are shown in Table 3 . On multivariate logistic regression, increasing pre-operative PSA was associated with increased odds of Gleason 7 or greater prostate cancer (p=0.002) ( Table 3) .
Amongst the 103 patients identified with prostate cancer on HoLEP, follow-up information was available for 48. Thirty-five of 48 patients (73%) were followed with active surveillance and had received no treatment for their diagnosed prostate cancer at last follow-up. Twelve of the 48 patients (25%) underwent some form of primary therapy: 7 received external beam radiation, 3 underwent radical prostatectomy, and 2 received hormonal therapy. One patient with advanced disease underwent bilateral orchiectomy. A total of three patients from this cohort had developed metastatic prostate cancer. At last follow-up, three patients from the surveillance cohort had died of non- . In contrast, our results suggest a potentially protective effect of BPH and obstructive symptoms on the presence of prostate cancer.
Whether this represents a true cause and effect phenomenon or merely isolating a prescreened patient population remains unknown. In any event, future research exploring the relationship between BPH and prostate cancer should be considered.
It is well established that the risk of prostate cancer increases with age. Because BPH is the primary contributor to PSA rise and, as previously discussed, BPH may impact the incidence of prostate cancer, the relationship of prostate cancer in aging men with BPH is less understood. Despite the fact that we report a significant increase in the adjusted odds of prostate cancer detection for each decade of life over 60 (Figure 1 ), we did not find that there was an association between age and Gleason score. Although the relationship between age and prostate cancer was anticipated based on prior research, it does provide valuable support that the relationship between prostate cancer and age remains present even in men with co-existing BPH and obstructive symptoms, although it does not appear to impact the clinical significance of malignancy.
Unlike the positive association between age and the presence of prostate cancer, the relationship between prostate size and prostate cancer has previously been shown to be inverse 18 . Similar to prior findings, our cohort again demonstrated a decrease in the odds of prostate cancer identification as prostate gland size increased beyond 30g.
Prior studies have hypothesized that the seemingly protective effect of larger glands harboring prostate cancer may be hormone mediated or related to a longer time before a 
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nodule penetrates the prostate capsule 19 . Additionally, pre-operative PSA, TRUS volume, and PSA density were all significant on univariate analysis. These findings suggest that prostate volume and PSA density may be important predictors of the presence of prostate cancer in men with BPH undergoing HoLEP and that these tests should be considered prior to surgery, particularly in men with higher risk of prostate cancer detection.
Although the limitations of PSA are well documented, PSA continues to be widely used as both a screening tool and a method of detecting prostate cancer recurrence 20, 21 .
Our results suggest that there is value in obtaining a PSA pre-operatively for men with BPH who are scheduled to undergo HoLEP. All patients with an elevated PSA should be considered for prostate biopsy or repeat prostate biopsy before surgery. If localized prostate cancer is identified prior to HoLEP, some of these men may elect to pursue alternative procedures to address both BPH and prostate cancer concomitantly.
Predicting the biologic behavior of prostate cancer found at HoLEP remains challenging. As documented in the past on autopsy and whole mount tissue studies, typically only 20-40% of prostate cancer originates in the prostate transition zone 16, 22 . Therefore, our data may be under-representing the true incidence and volume of disease present and is in no way a perfect surrogate for predicting prostate cancer- 
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however, it does limit conclusions that can be drawn regarding the prognosis of patients diagnosed with prostate cancer from HoLEP specimen.
The majority of patients were outside referrals and cancer management was often directed by the referring provider and not captured in our database. Ultimately, the creation of a treatment and surveillance algorithm for managing this patient population based on numerous pre-operative variables is warranted. Similar treatment flowcharts for prostate cancer and non-HoLEP related BPH procedures are well documented 23 . Future studies that evaluate PSA kinetics in patients with prostate cancer identified by HoLEP will aid in determining appropriate follow-up recommendations for this unique population. In our population of post-HoLEP patients with negative final prostate pathology, we anticipate PSA levels to fall below 1. If levels do not nadir below 1 or rise quickly in follow-up, we recommend repeat TRUS prostate biopsy as suspicion for prostate cancer is high. In the present study, our data offers potentially useful counseling data for patients prior to HoLEP regarding the risk of It is possible that a disproportionate number of patients who required subsequent therapy received follow-up at our institution, thus creating a selection bias in the descriptive findings that we present. Despite the stated limitations, our study represents one of the largest analyzed cohorts of prostate cancer in HoLEP patients.
Conclusion
The existence of incidentally detected prostate cancer at the time of HoLEP in men with BPH and obstruction is low and the majority of patients will have low grade disease. Men over 70 with smaller glands are at the highest risk of harboring prostate cancer in their analyzed tissue. Optimal treatment and surveillance strategies for management of men with prostate cancer after HoLEP need to be established. 
